BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mcnamara JJ, Mccolley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine 2019;7:325-35. [DOI: 10.1016/s2213-2600(18)30460-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 15.7] [Reference Citation Analysis]
Number Citing Articles
1 Saluzzo F, Riberi L, Messore B, Loré NI, Esposito I, Bignamini E, De Rose V. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells 2022;11:1243. [DOI: 10.3390/cells11071243] [Reference Citation Analysis]
2 Aurora P, Duncan JA, Lum S, Davies G, Wade A, Stocks J, Viviani L, Raywood E, Pao C, Ruiz G, Bush A. Early Pseudomonas aeruginosa predicts poorer pulmonary function in preschool children with cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.04.013] [Reference Citation Analysis]
3 Arnaud F, Stremler-Le Bel N, Reynaud-Gaubert M, Mancini J, Gaubert JY, Gorincour G. Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor. J Clin Med 2021;10:1999. [PMID: 34066942 DOI: 10.3390/jcm10091999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Dang Y, van Heusden C, Nickerson V, Chung F, Wang Y, Quinney NL, Gentzsch M, Randell SH, Moulton HM, Kole R, Ni A, Juliano RL, Kreda SM. Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung. Nucleic Acids Res 2021;49:6100-13. [PMID: 34107015 DOI: 10.1093/nar/gkab488] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022. [PMID: 35020677 DOI: 10.1213/ANE.0000000000005856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals (Basel) 2021;14:928. [PMID: 34577628 DOI: 10.3390/ph14090928] [Reference Citation Analysis]
7 Terlizzi V, Colangelo C, Marsicovetere G, D'Andria M, Francalanci M, Innocenti D, Masi E, Avarello A, Taccetti G, Amato F, Comegna M, Castaldo G, Salvatore D. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes (Basel) 2021;12:1178. [PMID: 34440351 DOI: 10.3390/genes12081178] [Reference Citation Analysis]
8 Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:585-93. [PMID: 33023304 DOI: 10.1164/rccm.202008-3177OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
9 Andrade A, Pizarro ME. Medicina de precisión en fibrosis quística. Revista Médica Clínica Las Condes 2022;33:44-50. [DOI: 10.1016/j.rmclc.2021.12.003] [Reference Citation Analysis]
10 Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther 2019;13:2405-12. [PMID: 31409974 DOI: 10.2147/DDDT.S153719] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. Reply to Eisenhut. Am J Physiol Lung Cell Mol Physiol 2021;321:L287-9. [PMID: 34233142 DOI: 10.1152/ajplung.00246.2021] [Reference Citation Analysis]
12 Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022;65:102239. [DOI: 10.1016/j.coph.2022.102239] [Reference Citation Analysis]
13 Calucho M, Gartner S, Barranco P, Fernández-Álvarez P, Pérez RG, Tizzano EF. Validation of nasospheroids to assay CFTR functionality and modulator responses in cystic fibrosis. Sci Rep 2021;11:15511. [PMID: 34330959 DOI: 10.1038/s41598-021-94798-x] [Reference Citation Analysis]
14 Eisenhut M. The significance of a lack of rhinorrhea in severe coronavirus 19 lung disease. Am J Physiol Lung Cell Mol Physiol 2021;320:L1194-5. [PMID: 34156889 DOI: 10.1152/ajplung.00066.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
16 King JA, Nichols A, Bentley S, Carr SB, Davies JC. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Pediatr Drugs. [DOI: 10.1007/s40272-022-00509-y] [Reference Citation Analysis]
17 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
18 Matos AM, Jordan P, Matos P. Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770. Front Mol Biosci 2021;8:812101. [PMID: 35004859 DOI: 10.3389/fmolb.2021.812101] [Reference Citation Analysis]
19 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
20 Stahl M, Joachim C, Kirsch I, Uselmann T, Yu Y, Alfeis N, Berger C, Minso R, Rudolf I, Stolpe C, Bovermann X, Liboschik L, Steinmetz A, Tennhardt D, Dörfler F, Röhmel J, Unorji-Frank K, Rückes-Nilges C, von Stoutz B, Naehrlich L, Kopp MV, Dittrich AM, Sommerburg O, Mall MA. Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. ERJ Open Res 2020;6:00408-2020. [PMID: 33263048 DOI: 10.1183/23120541.00408-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Jaques R, Shakeel A, Hoyle C. Novel therapeutic approaches for the management of cystic fibrosis. Multidiscip Respir Med 2020;15:690. [PMID: 33282281 DOI: 10.4081/mrm.2020.690] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Stahl M, Steinke E, Mall MA. Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes (Basel) 2021;12:803. [PMID: 34070354 DOI: 10.3390/genes12060803] [Reference Citation Analysis]
23 Caudri D, Turkovic L, de Klerk NH, Rosenow T, Murray CP, Steyerberg EW, Ranganathan SC, Sly P, Stick SM, Breuer O; AREST CF Study Group. A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis. Pediatr Pulmonol 2022;57:122-31. [PMID: 34596357 DOI: 10.1002/ppul.25712] [Reference Citation Analysis]
24 . Lumacaftor/ivacaftor for cystic fibrosis. Aust Prescr 2019;42:170-1. [PMID: 31631933 DOI: 10.18773/austprescr.2019.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Flume PA. The study of CFTR modulators in the very young. The Lancet Respiratory Medicine 2019;7:287-9. [DOI: 10.1016/s2213-2600(18)30503-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
27 Sawicki GS, Chilvers M, Mcnamara J, Naehrlich L, Saunders C, Sermet-gaudelus I, Wainwright CE, Ahluwalia N, Campbell D, Harris RS, Paz-diaz H, Shih JL, Davies JC. A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.02.003] [Reference Citation Analysis]
28 Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulm Ther 2020;6:303-13. [PMID: 32965659 DOI: 10.1007/s41030-020-00129-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
29 Haq I, Almulhem M, Soars S, Poulton D, Brodlie M. Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis. PGPM 2022;Volume 15:91-104. [DOI: 10.2147/pgpm.s245603] [Reference Citation Analysis]
30 Balfour-Lynn IM. Clinical papers of the year 2018 - Cystic fibrosis. Paediatr Respir Rev 2020;33:58-61. [PMID: 31053358 DOI: 10.1016/j.prrv.2019.03.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Cheng PC, Alexiou S, Rubenstein RC. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis. Expert Rev Respir Med 2019;13:417-23. [PMID: 30929526 DOI: 10.1080/17476348.2019.1602040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F, Collet C, Mas E, Languepin J, Fayon M, Beaufils F, Mittaine M. Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis. Front Pediatr 2021;9:744705. [PMID: 34869102 DOI: 10.3389/fped.2021.744705] [Reference Citation Analysis]
33 Costa E, Girotti S, Pauro F, Leufkens HGM, Cipolli M. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J Rare Dis 2022;17:188. [PMID: 35525974 DOI: 10.1186/s13023-022-02350-5] [Reference Citation Analysis]